Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cirius Eyes Phase III Plans In NASH With Interim Data Showing Liver, Metabolic Benefits

Oct 26 2018

• By Joseph Haas

scientists doing lab research on digital screen

Related Content

Cirius Suspects Insulin Resistance Is Underlying Key To NASH

Apr 11 2017

Related Companies

Cirius Therapeutics, Inc.

Takeda Pharmaceutical Co. Ltd.

Additional Topics

Research & Development Clinical Trials Liver & Hepatic BioPharmaceutical Metabolic Disorders

More from Alimentary/Metabolic

More from Therapeutic Category

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.